Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (5): 429-437.DOI: 10.3969/j.issn.1673-8640.2024.05.003
Previous Articles Next Articles
ZHANG Xiaoke1, CHU Yanrong2, WANG Rong3, CUI Facai3()
Received:
2023-03-04
Revised:
2023-11-18
Online:
2024-05-30
Published:
2024-06-12
CLC Number:
ZHANG Xiaoke, CHU Yanrong, WANG Rong, CUI Facai. Serum lncRNA HAND2-AS1 expression in cervical cancer patients and its effect on proliferation,invasion and migration of cervical cancer Caski cells[J]. Laboratory Medicine, 2024, 39(5): 429-437.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.05.003
基因 | 正义序列(5'~3') | 反义序列(5'~3') |
---|---|---|
lncRNA HAND2-AS1 | GGGTGTTTACGTAGACCAGAACC | CTTCCAAAAGCCTTCTGCCTTAG |
U6 | GCTTCGGCAGCACATATACTAAAAT | CGCTTCACGAATTTGCGTGTCAT |
基因 | 正义序列(5'~3') | 反义序列(5'~3') |
---|---|---|
lncRNA HAND2-AS1 | GGGTGTTTACGTAGACCAGAACC | CTTCCAAAAGCCTTCTGCCTTAG |
U6 | GCTTCGGCAGCACATATACTAAAAT | CGCTTCACGAATTTGCGTGTCAT |
临床病理特征 | 例数 | lncRNA HAND2-AS1 |
---|---|---|
年龄 | ||
≤45 岁 | 20 | 0.87±0.35 |
>45 岁 | 28 | 0.93±0.45 |
t 值 | 0.566 | |
P 值 | 0.574 | |
肿瘤大小 | ||
≤3 cm | 24 | 1.07±0.47 |
>3 cm | 24 | 0.74±0.24 |
t 值 | 3.103 | |
P 值 | 0.003 | |
组织类型 | ||
鳞状细胞癌 | 32 | 0.95±0.39 |
腺癌 | 16 | 0.81±0.43 |
t 值 | 1.135 | |
P 值 | 0.262 | |
宫颈浸润深度 | ||
≤2/3 | 21 | 1.03±0.45 |
>2/3 | 27 | 0.83±0.35 |
t 值 | 1.680 | |
P 值 | 0.100 | |
FIGO分期 | ||
Ⅰ~Ⅱ 期 | 33 | 1.02±0.41 |
Ⅲ~Ⅵ 期 | 15 | 0.66±0.27 |
t 值 | 3.031 | |
P 值 | 0.004 | |
分化程度 | ||
中高分化 | 32 | 0.95±0.42 |
低分化 | 16 | 0.82±0.37 |
t 值 | 1.058 | |
P 值 | 0.296 | |
淋巴转移 | ||
无 | 23 | 1.05±0.40 |
有 | 25 | 0.77±0.37 |
t 值 | 2.512 | |
P 值 | 0.016 |
临床病理特征 | 例数 | lncRNA HAND2-AS1 |
---|---|---|
年龄 | ||
≤45 岁 | 20 | 0.87±0.35 |
>45 岁 | 28 | 0.93±0.45 |
t 值 | 0.566 | |
P 值 | 0.574 | |
肿瘤大小 | ||
≤3 cm | 24 | 1.07±0.47 |
>3 cm | 24 | 0.74±0.24 |
t 值 | 3.103 | |
P 值 | 0.003 | |
组织类型 | ||
鳞状细胞癌 | 32 | 0.95±0.39 |
腺癌 | 16 | 0.81±0.43 |
t 值 | 1.135 | |
P 值 | 0.262 | |
宫颈浸润深度 | ||
≤2/3 | 21 | 1.03±0.45 |
>2/3 | 27 | 0.83±0.35 |
t 值 | 1.680 | |
P 值 | 0.100 | |
FIGO分期 | ||
Ⅰ~Ⅱ 期 | 33 | 1.02±0.41 |
Ⅲ~Ⅵ 期 | 15 | 0.66±0.27 |
t 值 | 3.031 | |
P 值 | 0.004 | |
分化程度 | ||
中高分化 | 32 | 0.95±0.42 |
低分化 | 16 | 0.82±0.37 |
t 值 | 1.058 | |
P 值 | 0.296 | |
淋巴转移 | ||
无 | 23 | 1.05±0.40 |
有 | 25 | 0.77±0.37 |
t 值 | 2.512 | |
P 值 | 0.016 |
组别 | lncRNA HAND2-AS1 | 细胞增殖活性(A值) | 侵袭细胞数/(个·高倍镜视野-1) | ||
---|---|---|---|---|---|
24 h | 48 h | 72 h | |||
过表达组 | 1.72±0.12 | 0.44±0.02 | 0.51±0.03 | 0.56±0.01 | 192.7±26.9 |
阴性对照组 | 1.03±0.06 | 0.46±0.02 | 0.59±0.02 | 0.77±0.03 | 294.7±23.6 |
t 值 | 8.640 | 1.563 | 6.502 | 10.290 | 4.929 |
P 值 | 0.001 | 0.129 | 0.003 | 0.001 | 0.008 |
组别 | 划痕愈合率/% | p-PI3K蛋白 | PI3K蛋白 | p-Akt蛋白 | Akt蛋白 |
过表达组 | 41.1±2.9 | 1.10±0.07 | 1.07±0.05 | 1.04±0.03 | 1.06±0.04 |
阴性对照组 | 63.9±5.8 | 0.34±0.07 | 1.02±0.06 | 0.23±0.05 | 1.05±0.06 |
t 值 | 6.075 | 13.100 | 1.058 | 26.720 | 0.259 |
P 值 | 0.004 | <0.001 | 0.235 | <0.001 | 0.408 |
组别 | lncRNA HAND2-AS1 | 细胞增殖活性(A值) | 侵袭细胞数/(个·高倍镜视野-1) | ||
---|---|---|---|---|---|
24 h | 48 h | 72 h | |||
过表达组 | 1.72±0.12 | 0.44±0.02 | 0.51±0.03 | 0.56±0.01 | 192.7±26.9 |
阴性对照组 | 1.03±0.06 | 0.46±0.02 | 0.59±0.02 | 0.77±0.03 | 294.7±23.6 |
t 值 | 8.640 | 1.563 | 6.502 | 10.290 | 4.929 |
P 值 | 0.001 | 0.129 | 0.003 | 0.001 | 0.008 |
组别 | 划痕愈合率/% | p-PI3K蛋白 | PI3K蛋白 | p-Akt蛋白 | Akt蛋白 |
过表达组 | 41.1±2.9 | 1.10±0.07 | 1.07±0.05 | 1.04±0.03 | 1.06±0.04 |
阴性对照组 | 63.9±5.8 | 0.34±0.07 | 1.02±0.06 | 0.23±0.05 | 1.05±0.06 |
t 值 | 6.075 | 13.100 | 1.058 | 26.720 | 0.259 |
P 值 | 0.004 | <0.001 | 0.235 | <0.001 | 0.408 |
组别 | lncRNA HAND2-AS1 | 细胞增殖活性(A值) | 侵袭细胞数/(个·高倍镜视野-1) | ||
---|---|---|---|---|---|
24 h | 48 h | 72 h | |||
干扰组 | 0.36±0.08 | 0.45±0.04 | 0.63±0.04 | 0.86±0.04 | 387.3±23.6 |
干扰对照组 | 1.03±0.03 | 0.42±0.03 | 0.56±0.04 | 0.74±0.06 | 295.3±24.6 |
t 值 | 13.770 | 2.844 | 4.783 | 9.071 | 4.673 |
P 值 | <0.001 | 0.047 | 0.013 | 0.002 | 0.010 |
组别 | 划痕愈合率/% | p-PI3K蛋白 | PI3K蛋白 | p-Akt蛋白 | Akt蛋白 |
干扰组 | 57.1±4.0 | 0.99±0.05 | 0.99±0.02 | 0.98±0.07 | 1.04±0.07 |
干扰对照组 | 32.1±3.6 | 1.27±0.11 | 1.03±0.03 | 1.38±0.09 | 0.98±0.02 |
t 值 | 8.639 | 4.037 | 1.761 | 6.113 | 1.442 |
P 值 | 0.001 | 0.032 | 0.155 | 0.015 | 0.225 |
组别 | lncRNA HAND2-AS1 | 细胞增殖活性(A值) | 侵袭细胞数/(个·高倍镜视野-1) | ||
---|---|---|---|---|---|
24 h | 48 h | 72 h | |||
干扰组 | 0.36±0.08 | 0.45±0.04 | 0.63±0.04 | 0.86±0.04 | 387.3±23.6 |
干扰对照组 | 1.03±0.03 | 0.42±0.03 | 0.56±0.04 | 0.74±0.06 | 295.3±24.6 |
t 值 | 13.770 | 2.844 | 4.783 | 9.071 | 4.673 |
P 值 | <0.001 | 0.047 | 0.013 | 0.002 | 0.010 |
组别 | 划痕愈合率/% | p-PI3K蛋白 | PI3K蛋白 | p-Akt蛋白 | Akt蛋白 |
干扰组 | 57.1±4.0 | 0.99±0.05 | 0.99±0.02 | 0.98±0.07 | 1.04±0.07 |
干扰对照组 | 32.1±3.6 | 1.27±0.11 | 1.03±0.03 | 1.38±0.09 | 0.98±0.02 |
t 值 | 8.639 | 4.037 | 1.761 | 6.113 | 1.442 |
P 值 | 0.001 | 0.032 | 0.155 | 0.015 | 0.225 |
[1] |
COHEN P A, JHINGRAN A, OAKNIN A, et al. Cervical cancer[J]. Lancet, 2019, 393(10167):169-182.
DOI PMID |
[2] | XIA C, DONG X, LI H, et al. Cancer statistics in China and United States,2022:profiles,trends,and determinants[J]. Chin Med J (Engl), 2022, 135(5):584-590. |
[3] | 陈号, 夏昌发, 由婷婷, 等. 中国女性宫颈癌负担快速上升的原因及其应对措施[J]. 中华流行病学杂志, 2022, 43(5):761-765. |
[4] | World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem[EB/OL]. (2020-11-17) [2023-01-07]. https://www.who.int/zh/news/item/17-11-2020-a-cervical-cancer-free-future-first-ever-global-commitment-to-eliminate-a-cancer. |
[5] | DE GEUS V, EWING-GRAHAM P C, DE KONING W, et al. Identifying molecular changes in early cervical cancer samples of patients that developed metastasis[J]. Front Oncol, 2022, 11:715077. |
[6] | HASHEMI M, MOOSAVI M S, ABED H M, et al. Long non-coding RNA (lncRNA)H19 in human cancer:from proliferation and metastasis to therapy[J]. Pharmacol Res, 2022, 184:106418. |
[7] | 聂明月, 辛乐, 叶红. 长链非编码RNA MALAT1在宫颈癌中作用的研究进展[J]. 中华实用诊断与治疗杂志, 2022, 36(3):321-324. |
[8] | YU L, LI H, LI Z, et al. Long non-coding RNA HAND2-AS1 inhibits growth and migration of gastric cancer cells through regulating the miR-590-3p/KCNT2 axis[J]. Onco Targets Ther, 2020, 13:3187-3196. |
[9] | WEI P, YANG J, ZHANG D, et al. LncRNA HAND2-AS1 regulates prostate cancer cell growth through targeting the miR-106a-5p/RBM24 axis[J]. Onco Targets Ther, 2020, 13:4523-4531. |
[10] | DONG G, WANG X, JIA Y, et al. HAND2-AS1 works as a ceRNA of miR-3118 to suppress proliferation and migration in breast cancer by upregulating PHLPP2[J]. Biomed Res Int, 2020, 2020:8124570. |
[11] | PPOALIS M L, RAMIREZ S I, LEACH K M, et al. Improving cervical cancer screening rates:a scoping review of resources and interventions[J]. Cancer Causes Control, 2022, 33(11):1325-1333. |
[12] | LI T, LAI Y, YUAN J. The diagnostic accuracy of TCT + HPV-DNA for cervical cancer:systematic review and meta-analysis[J]. Ann Transl Med, 2022, 10(14):761. |
[13] |
LI H, LI L, SUN J, et al. Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions[J]. Pak J Med Sci, 2022, 38(6):1471-1476.
DOI PMID |
[14] | ARBYN M, SIMON M, DE SANJOSÉ, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening:a systematic review and meta-analysis[J]. Lancet Oncol, 2022, 23(7):950-960. |
[15] |
CAI Y, HUANG Y, ZHANG J, et al. LncRNA CBR3-AS1 predicts a poor prognosis and promotes cervical cancer progression through the miR-3163/LASP1 pathway[J]. Neoplasma, 2022, 69(6):1406-1417.
DOI PMID |
[16] | LIU M Y, LI N. The diagnostic value of lncRNA HOTAIR for cervical carcinoma in vaginal discharge and serum[J]. Medicine(Baltimore), 2023, 102(26):e34042. |
[17] |
CAO X, YAO J, JIA M, et al. Serum CCAT2 as a biomarker for adjuvant diagnosis and prognostic prediction of cervical cancer[J]. J Ovarian Res, 2022, 15(1):20.
DOI PMID |
[18] |
GAO Y, ZOU T, LIANG W, et al. Long non-coding RNA HAND2-AS1 delays cervical cancer progression via its regulation on the microRNA-21-5p/TIMP3/VEGFA axis[J]. Cancer Gene Ther, 2021, 28(6):619-633.
DOI PMID |
[19] | HU J, WANG M, YANG Y, et al. LncRNA DLEU2 silencing impedes the migration,invasion and EMT in gastric cancer cell by suppressing PI3K/AKT signaling pathway[J]. Immunopharmacol Immunotoxicol, 2022, 44(5):719-731. |
[20] | SHI W J, LIU H, GE Y F, et al. LINC00673 exerts oncogenic function in cervical cancer by negatively regulating miR-126-5p expression and activates PTEN/PI3K/AKT signaling pathway[J]. Cytokine, 2020, 136:155286. |
[21] | 李沫, 宓淑芳, 王孝信. lncRNA-CCAT1通过调控PI3K/Akt/mTOR信号通路对宫颈癌HeLa细胞自噬的影响[J]. 中国免疫学杂志, 2021, 37(15):1855-1859. |
[22] | GAO T, DAI X, JIANG Y, et al. LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of non-small cell lung cancer cells by inactivating PI3K/Akt pathway[J]. Biosci Rep, 2020, 40(11):BSR20201870. |
[23] | LI L, LI L, HU L, et al. Long non-coding RNA HAND2-AS1/miR-106a/PTEN axis re-sensitizes cisplatin-resistant ovarian cells to cisplatin treatment[J]. Mol Med Rep, 2021, 24(5):762. |
[1] | FANG Dandong, CHENG Gang, HUANG Wei, LIU Xiaonan, MAO Jian, HOU Baosen, LIU Shimin. Expression of lncRNA SOX21-AS1 and miR-875-5p in glioma tissues and relationship with prognosis of patients [J]. Laboratory Medicine, 2024, 39(3): 209-214. |
[2] | ZHANG Feifei, WANG Jingwen, ZHANG Yuexin, ZHENG Dawei, MEN Xiang. Correlation between lncRNA MIR155HG and pulmonary function in patients with COPD and its auxiliary diagnosis value for AECODP [J]. Laboratory Medicine, 2024, 39(1): 31-36. |
[3] | DAI Hongjian, CUI Haining, LI Yanfeng, CUI Hongmei. Promoting effect of miR-155-5p targeting ARID2 on oral squamous cell carcinoma [J]. Laboratory Medicine, 2024, 39(1): 87-94. |
[4] | YANG Yuqiang, QUAN Xiaoli, WANG Liuyu, XIAN Wenfeng, YANG Hong. Expression of RRBP1 in osteosarcoma tissues and its effect on cell biological characteristics [J]. Laboratory Medicine, 2023, 38(9): 842-848. |
[5] | PAN Xin, LÜ Ying, LI Yang, LI Rongguo. Effects of miR-24-3p targeting CHD5 on migration,invasion and radiosensitivity of thyroid cancer cells [J]. Laboratory Medicine, 2023, 38(7): 640-646. |
[6] | WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691. |
[7] | LIANG Chaohui, ZHAO Fan, LIU Qianwen. Relationship between macrophage migration inhibitory factor and carotid vascular calcification in elderly patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2023, 38(5): 460-465. |
[8] | ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210. |
[9] | GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996. |
[10] | WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45. |
[11] | ZHANG Yaxu, CUI Yanwei, LIU Ziyan. Preliminary research for the determination of HPV E6/E7 mRNA by nucleic acid molecular hybridization-flow cytometry [J]. Laboratory Medicine, 2023, 38(1): 46-50. |
[12] | SHANG Zhenjun, WEI Wei, LIU Ruihan. Effect of inhibiting PTBP1 on the proliferation and invasiveness of choroidal melanoma cells [J]. Laboratory Medicine, 2023, 38(1): 51-55. |
[13] | WANG Yuqing, ZHANG Yue, XU Wen, CUI Zhongqi. Construction and clinical application of colon cancer prognostic risk model of ferroptosis-related lncRNA [J]. Laboratory Medicine, 2022, 37(8): 720-728. |
[14] | JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609. |
[15] | JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, DONG Wei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Yifei. Expression level of lncRNA SNHG15 in gastric cancer and clinical significance [J]. Laboratory Medicine, 2022, 37(5): 409-412. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||